Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.
JogalekarMPVeerabathiniAGangadaranP.Novel 2019 coronavirus: genome structure, clinical trials, and outstanding questions.Exp Biol Med (Maywood)2020;245:964–9
2.
JogalekarMPVeerabathiniAGangadaranP.SARS-CoV-2 variants: a double-edged sword.Exp Biol Med (Maywood)2021;246:1721–6
3.
ManivannanMJogalekarMPKavithaMSMaranBAVGangadaranP.A mini-review on the effects of COVID-19 on younger individuals.Exp Biol Med (Maywood)2021;246:293–7
4.
ZhouFYuTDuRFanGLiuYLiuZXiangJWangYSongBGuXGuanLWeiYLiHWuXXuJTuSZhangYChenHCaoB.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet2020; 395:1054–62
5.
LiBYangJZhaoFZhiLWangXLiuLBiZZhaoY.Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.Clin Res Cardiol2020;109:531–8
6.
VenkateshNPaldusBLeeMHMacIsaacRJJenkinsAJO’NealDN.COVID-19, type 1 diabetes clinical practice, research, and remote medical care: a view from the land down-under.J Diabetes Sci Technol2020;14:803–4
7.
KnappS.Diabetes and infection: is there a link? A mini-review.Gerontology2013;59:99–104
WuZMcGooganJM.Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.JAMA2020;323:1239–42
10.
FehrenbachHKasperMTschernigTShearmanMSSchuhDMüllerM.Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung.Cell Mol Biol (Noisy-le-grand)1998;44:1147–57
CodoACDavanzoGGMonteiroLdeBde SouzaGFMuraroSPVirgilioda-Silva-JVProdonoffJSCarregariVCde Biagi JuniorCAOCrunfliFJimenez RestrepoJLVendraminiPHReis-de-OliveiraGBispo Dos SantosKToledo-TeixeiraDAParisePLMartiniMCMarquesRECarmoHRBorinACoimbraLDBoldriniVOBrunettiNSVieiraASMansourEUlafRGBernardesAFNunesTARibeiroLCPalmaACAgrelaMVMorettiMLSpositoACPereiraFBVellosoLAVinoloMARDamasioAProença-MódenaJLCarvalhoRFMoriMAMartins-de-SouzaDNakayaHIFariasASMoraes-VieiraPM.Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis.Cell Metab2020;32:437–4465
13.
LimSBaeJHKwonHSNauckMA.COVID-19 and diabetes mellitus: from pathophysiology to clinical management.Nat Rev Endocrinol2021;17:11–30
14.
MuniyappaRGubbiS.COVID-19 pandemic, coronaviruses, and diabetes mellitus.Am J Physiol Endocrinol Metab2020;318:E736–41
15.
PhilipsBJMeguerJXRedmanJBakerEH.Factors determining the appearance of glucose in upper and lower respiratory tract secretions.Intensive Care Med2003;29:2204–10
16.
SchofieldJLeelarathnaLThabitH.COVID-19: impact of and on diabetes.Diabetes Ther2020;11:1429–35
17.
BrufskyA.Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.J Med Virol2020;92:770–5
18.
BatlleDJose SolerMYeM.ACE2 and diabetes: ACE of ACEs.Diabetes2010;59:2994–6
19.
ZhengXZhengXWangXMaZGupta SunkariVBotusanITakedaTBjörklundAInoueMCatrinaS-BBrismarKPoellingerLPereiraTS.Acute hypoxia induces apoptosis of pancreatic β-cell by activation of the unfolded protein response and upregulation of CHOP.Cell Death Dis2012;3:e322
20.
UgwuezeCVEzeokpoBCNnolimBIAgimEAAnikpoNCOnyekachiKE.COVID-19 and diabetes mellitus: the link and clinical implications.Dubai Diabetes Endocrinol J2020;26:69–77
21.
YeQWangBMaoJ.The pathogenesis and treatment of the “cytokine storm” in COVID-19.J Infect2020;80:607–13
22.
WangJJiangMChenXMontanerLJ.Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.J Leukoc Biol2020;108:17–41
23.
ZhangWWangGXuZ-GTuHHuFDaiJChangYChenYLuYZengHCaiZHanFXuCJinGSunLPanB-SLaiS-WHsuC-CXuJChenZ-ZLiH-YSethPHuJZhangXLiHLinH-K.Lactate is a natural suppressor of RLR signaling by targeting MAVS.Cell2019;178:176–189.e15
24.
WondmkunYT.Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications.Diabetes Metab Syndr Obes2020;13:3611–6
25.
BarberTM.COVID-19 and diabetes mellitus: implications for prognosis and clinical management.Expert Rev Endocrinol Metab2020;15:227–36
26.
RaoSLauASoHC.Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a Mendelian randomization analysis highlights tentative relevance of diabetes-related traits.Diabetes Care2020;43:1416–26
27.
IeronymakiEDaskalakiMGLyroniKTsatsanisC.Insulin signaling and insulin resistance facilitate trained immunity in macrophages through metabolic and epigenetic changes.Front Immunol2019;10:1330
28.
Rizo-TéllezSAMéndez-GarcíaLAFlores-RebolloCAlba-FloresFAlcántara-SuárezRManjarrez -ReynaANBaltazar-LópezNHernández-GuzmánVALeón-PedrozaJIZapata-ArenasRGonzález-ChávezAHernández-RuízJCarrillo-RuízJDSerrano-LoyolaRGuerrero-AvendañoGMLEscobedoG.The neutrophil-to-monocyte ratio and lymphocyte-to-neutrophil ratio at admission predict in-hospital mortality in Mexican patients with severe SARS-CoV-2 infection (Covid-19).Microorganisms2020;8:1560
29.
MaessenDEStehouwerCDSchalkwijkCG.The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.Clin Sci (Lond)2015;128:839–61
30.
SellegounderDZafariPRajabinejadMTaghadosiMKapahiP.Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis.Int Immunopharmacol2021;98:107806
31.
RojasALindnerCGonzàlezIMoralesMA.Advanced-glycation end-products axis: a contributor to the risk of severe illness from COVID-19 in diabetes patients.World J Diabetes2021;12:590–602
32.
MulrennanSBalticSAggarwalSWoodJMirandaAFrostFKayeJThompsonPJ.The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes.Sci Rep2015;5:8931
33.
ChikazawaMShibataTHatasaYHiroseSOtakiNNakashimaFItoMMachidaSMaruyamaSUchidaK.Identification of C1q as a binding protein for advanced glycation end products.Biochemistry2016;55:435–46
34.
ManzoG.COVID-19 as an immune complex hypersensitivity in antigen excess conditions: theoretical pathogenetic process and suggestions for potential therapeutic interventions.Front Immunol2020;11:566000
35.
SpanakisEK.Diabetes and technology in the covid-19 pandemic crisis.J Diabetes Sci Technol2021;15:377–8
36.
SinghAKGuptaRGhoshAMisraA.Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations.Diabetes Metab Syndr2020;14:303–10
37.
CDCMMWR. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020.MMWR Morb Mortal Wkly Rep2020;69:382–6
38.
LiuJLiuYXiangPPuLXiongHLiCZhangMTanJXuYSongRSongMWangLZhangWHanBYangLWangXZhouGZhangTLiBWangYChenZWangX.Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.J Transl Med2020;18:206
39.
WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongY.Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.JAMA Intern Med2020;180:934–43
40.
GuoWLiMDongYZhouHZhangZTianCQinRWangHShenYDuKZhaoLFanHLuoSHuD.Diabetes is a risk factor for the progression and prognosis of COVID-19.Diabetes Metab Res Rev2020;36:e3319
41.
NikniazZSomiMHDinevariMFTaghizadiehAMokhtariL.Diabesity associates with poor COVID-19 outcomes among hospitalized patients.J Obes Metab Syndr2021;30:149–54
42.
ZhangJKongWXiaPXuYLiLLiQYangLWeiQWangHLiHZhengJSunHXiaWLiuGZhongXQiuKLiYWangHWangYSongXLiuHXiongSLiuYCuiZHuYChenLPanAZengT.Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019.Front Endocrinol (Lausanne)2020;11:525
43.
PalRBhadadaSK.COVID-19 and diabetes mellitus: an unholy interaction of two pandemics.Diabetes Metab Syndr2020;14:513–7
44.
PradhanADMansonJERifaiNBuringJERidkerPM.C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.JAMA2001;286:327–34
45.
AdamSSKeyNSGreenbergCS.D-dimer antigen: current concepts and future prospects.Blood2009;113:2878–87
46.
KlocMGhobrialRMLewickiSKubiakJZ.Macrophages in diabetes mellitus (DM) and COVID-19: do they trigger DM?J Diabetes Metab Disord2020;19:2045–8
47.
ChenGLiXGongZXiaHWangYWangXHuangYBarajas-MartinezHHuD.Hypertension as a sequela in patients of SARS-CoV-2 infection.PLoS ONE2021;16:e0250815
48.
ErenerS.Diabetes, infection risk and COVID-19.Mol Metab2020;39: 101044
49.
ZhuLSheZ-GChengXQinJ-JZhangX-JCaiJLeiFWangHXieJWangWLiHZhangPSongXChenXXiangMZhangCBaiLXiangDChenM-MLiuYYanYLiuMMaoWZouJLiuLChenGLuoPXiaoBZhangCZhangZLuZWangJLuHXiaXWangDLiaoXPengGYePYangJYuanYHuangXGuoJZhangB-HLiH.Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.Cell Metab2020;31:1068–10773
50.
LeeMSLeeRKoCWMoonJE.Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study.J Yeungnam Med Sci2022;39:46–52
